| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1037644695 |
| P356 | DOI | 10.1186/AR628 |
| P953 | full work available at URL | https://arthritis-research.biomedcentral.com/counter/pdf/10.1186/ar628 |
| https://europepmc.org/articles/PMC165038 | ||
| https://europepmc.org/articles/PMC165038?pdf=render | ||
| P3181 | OpenCitations bibliographic resource ID | 3575318 |
| P932 | PMC publication ID | 165038 |
| P698 | PubMed publication ID | 12718748 |
| P5875 | ResearchGate publication ID | 10783778 |
| P2093 | author name string | John D. Reveille | |
| Khanh T. Ho | |||
| P2860 | cites work | Limited cutaneous systemic sclerosis associated with MPO-ANCA positive renal small vessel vasculitis of the microscopic polyangiitis type | Q74288858 |
| HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients | Q74502807 | ||
| Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients | Q74508437 | ||
| Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing | Q74714793 | ||
| ANTINUCLEAR AND PRECIPITATING AUTOANTIBODIES IN PROGRESSIVE SYSTEMIC SCLEROSIS | Q76587709 | ||
| Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis | Q77170117 | ||
| Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay | Q77359415 | ||
| Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival | Q77754710 | ||
| Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis | Q77852708 | ||
| Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases | Q77967492 | ||
| Centrosome proteins: a major class of autoantigens in scleroderma | Q77996271 | ||
| Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis | Q78116630 | ||
| Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis | Q78116637 | ||
| Identity of the RNase MRP- and RNase P-associated Th/To autoantigen | Q78667371 | ||
| Variability of tissue-localizing properties of serum from patients with different disease states | Q79385677 | ||
| Autoantibodies directed to novel components of the PM/Scl complex, the human exosome | Q24292404 | ||
| CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis | Q24307548 | ||
| CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization | Q24318574 | ||
| Human CENP-A contains a histone H3 related histone fold domain that is required for targeting to the centromere | Q24337253 | ||
| CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate | Q24337772 | ||
| An intact Box C sequence in the U3 snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs | Q24564832 | ||
| The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma) | Q24597261 | ||
| Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations | Q24678420 | ||
| Autoantibodies against DNA double-strand break repair proteins | Q28203225 | ||
| Marker antibodies in scleroderma and polymyositis: clinical associations | Q28253274 | ||
| Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34,000; pI, 8.5) rich in NG,NG-dimethylarginine | Q28300608 | ||
| Anti-NuMA antibodies: an uncommon specificity in scleroderma sera. | Q30741491 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis | Q33398459 | ||
| The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases | Q33498243 | ||
| Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations | Q33562211 | ||
| Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation | Q33566329 | ||
| Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting | Q33570128 | ||
| Scleroderma overlap syndromes. | Q33883683 | ||
| Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis | Q33895346 | ||
| Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. | Q34004771 | ||
| Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies | Q34520516 | ||
| Autoantibody to RNA polymerase I in scleroderma sera | Q34553988 | ||
| Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients | Q34559161 | ||
| Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature | Q34654595 | ||
| Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations | Q35009486 | ||
| Mixed connective tissue disease--goodbye to all that | Q35366597 | ||
| Antigen specificity of antihistone antibodies in systemic sclerosis | Q35548117 | ||
| Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases | Q35551919 | ||
| Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III | Q35611011 | ||
| Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis) | Q35822079 | ||
| Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes | Q71276074 | ||
| Follow-up of 151 patients with high-titer U1RNP antibodies | Q71502424 | ||
| Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis | Q71537249 | ||
| Analysis of anti-U1 RNA antibodies in patients with connective tissue disease. Association with HLA and clinical manifestations of disease | Q71634766 | ||
| Clinical Significance of Anticardiolipin Antibodies in Patients with Systemic Sclerosis | Q71788190 | ||
| Antibodies to centromere and centriole in scleroderma spectrum disorders | Q71995386 | ||
| Contrasting molecular patterns of mhc class ii alleles associated with the anti‐sm and anti‐rnp precipitin autoantibodies in systemic lupus erythematosus | Q72068467 | ||
| Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis | Q72296621 | ||
| Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study | Q72429136 | ||
| Autoantibody reactive with RNA polymerase III in systemic sclerosis | Q72544268 | ||
| Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome | Q72611213 | ||
| Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma | Q72686968 | ||
| Anticentromere antibodies (ACA): clinical distribution and disease specificity | Q72792454 | ||
| Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. The Italian Society of Laboratory Medicine Study Group on the Diagnosis of Autoimmune diseases | Q73038166 | ||
| Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases | Q73076933 | ||
| Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis | Q73293889 | ||
| Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma | Q73363935 | ||
| Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis | Q73385984 | ||
| Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies | Q73497702 | ||
| Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus | Q73565819 | ||
| Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin) | Q73797347 | ||
| Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis | Q73806764 | ||
| The frequency and significance of anticardiolipin antibodies in scleroderma | Q73892300 | ||
| Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases | Q74202383 | ||
| Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis | Q74258579 | ||
| Immunogenetic associations of scleroderma-related antinuclear antibodies | Q68800363 | ||
| Clinical implications of ribonucleoprotein antibody | Q68820332 | ||
| Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma) | Q69024312 | ||
| Sjögren's syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study | Q69637477 | ||
| Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma | Q69735280 | ||
| Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma | Q69742308 | ||
| Antinuclear antibodies in progressive systemic sclerosis | Q69912838 | ||
| Antinuclear antibodies in the relatives of patients with systemic sclerosis | Q69938458 | ||
| High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients | Q70124748 | ||
| Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis | Q70238267 | ||
| Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies | Q70344475 | ||
| Clinical characteristics of patients with rheumatic disorders who possess antibodies against ribonucleoprotein particles | Q70985116 | ||
| A long-term longitudinal study of anticentromere antibodies | Q71002241 | ||
| Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis | Q71160324 | ||
| The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis | Q71245376 | ||
| Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis | Q36182730 | ||
| Significance of anticentromere antibody in idiopathic Raynaud's syndrome | Q39295867 | ||
| Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis | Q39296891 | ||
| Pulmonary involvement in systemic sclerosis. Association with anti-Scl 70 antibody and digital pitting | Q39304871 | ||
| Antiendothelial Cell Antibodies: Useful Markers of Systemic Sclerosis | Q39448876 | ||
| Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis | Q39461641 | ||
| Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension | Q39463358 | ||
| Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. | Q39477473 | ||
| Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants | Q39563893 | ||
| Renal vascular damage in Japanese patients with systemic sclerosis | Q39564430 | ||
| Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss | Q39608534 | ||
| Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status | Q41060557 | ||
| Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma | Q41107777 | ||
| The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon | Q41214015 | ||
| A human centromere antigen (CENP-B) interacts with a short specific sequence in alphoid DNA, a human centromeric satellite | Q41590805 | ||
| Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies | Q41605342 | ||
| A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity | Q41615585 | ||
| Human anticentriole autoantibody in patients with scleroderma and Raynaud's phenomenon | Q42455112 | ||
| The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays | Q43764553 | ||
| Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients | Q43878884 | ||
| Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study | Q43941513 | ||
| Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. | Q44001432 | ||
| Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients | Q44824715 | ||
| Autoantibody to th ribonucleoprotein (nucleolar 7–2 rna protein particle) in patients with systemic sclerosis | Q45086042 | ||
| Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. | Q46702695 | ||
| African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease | Q46905919 | ||
| Anti-fibrillarin antibodies in systemic sclerosis | Q46989762 | ||
| Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren's overlap to the CREST variant of scleroderma | Q47794698 | ||
| Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients | Q47964671 | ||
| Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. | Q50969873 | ||
| Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. | Q53991177 | ||
| Anti-helix-loop-helix domain antibodies: discovery of autoantibodies that inhibit DNA binding activity of human centromere protein B (CENP-B) | Q54681535 | ||
| The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl | Q57089713 | ||
| Longitudinal Study of Anticentromere and Antitopoisomerase-I Isotypes | Q60449604 | ||
| Anticentromere Autoantibodies | Q60449609 | ||
| Detection of anticentromere antibodies using cloned autoantigen cenp-Bl | Q60449654 | ||
| HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies | Q62748642 | ||
| Epitope mapping of human centromere autoantigen centromere protein C (CENP-C); heterogeneity of anti-CENP-C response in rheumatic diseases. | Q64975793 | ||
| Association of Antibodies to Ribonucleoprotein and Sm Antigens with Mixed Connective-Tissue Disease, Systemic Lupus Erythematosus and Other Rheumatic Diseases | Q66888389 | ||
| Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease | Q67264348 | ||
| Are ACA and Scl 70 antibodies mutually exclusive? | Q67278888 | ||
| Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations | Q67569082 | ||
| Cutaneous and serologic subsets of systemic sclerosis | Q67865327 | ||
| Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations | Q68383909 | ||
| Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus | Q68488810 | ||
| Sjögren's syndrome in progressive systemic sclerosis | Q68508916 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | globulins | Q321710 |
| rheumatology | Q327657 | ||
| blood proteins | Q425056 | ||
| autoantibody | Q785022 | ||
| systemic scleroderma | Q5340515 | ||
| P304 | page(s) | 80-93 | |
| P577 | publication date | 2003-02-12 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | The clinical relevance of autoantibodies in scleroderma | |
| P478 | volume | 5 |
| Q40891723 | A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand |
| Q50304651 | A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma |
| Q39519878 | A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis |
| Q48115705 | A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults |
| Q36129874 | Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus |
| Q35661256 | Antinuclear antibody-negative systemic sclerosis |
| Q42167437 | Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis |
| Q57612771 | Association study of CRP gene in systemic sclerosis in European Caucasian population |
| Q33320557 | Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis |
| Q28085026 | Autoantibodies in systemic sclerosis: unanswered questions |
| Q37778576 | Autoantibody Testing for Autoimmune Disease |
| Q45917138 | Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. |
| Q37730018 | Biomarkers in systemic sclerosis |
| Q64114060 | Cardiac phenotype in mouse models of systemic autoimmunity |
| Q55396705 | Cerebellar atrophy in systemic sclerosis. |
| Q28750130 | Clinical and serological evaluation of a novel CENP-A peptide based ELISA |
| Q83298992 | Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis |
| Q37690559 | Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis |
| Q34277474 | Comparing HLA shared epitopes in French Caucasian patients with scleroderma |
| Q38156227 | Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development |
| Q39437352 | Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. |
| Q40491920 | Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement |
| Q35352582 | Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis |
| Q50683587 | Early identification of vascular damage in patients with systemic sclerosis. |
| Q92003078 | Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease |
| Q52939870 | Evaluation and management approaches for scleroderma lung disease. |
| Q35975992 | Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan |
| Q37300987 | Exercise capacity in relation to autoantibodies in systemic sclerosis patients |
| Q40418873 | Fever of unknown origin secondary to type I crescentic glomerulonephritis and anti-SCl 70 antibodies without clinical manifestations of systemic sclerosis |
| Q92217574 | HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry |
| Q50449354 | IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis. |
| Q44751936 | Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities |
| Q92069008 | Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention |
| Q46176565 | Interstitial lung disease in South Africans with systemic sclerosis. |
| Q41235272 | Low doses of mercuric chloride cause the main features of anti-nucleolar autoimmunity in female outbred CFW mice |
| Q33863272 | Mercury exposure, serum antinuclear/antinucleolar antibodies, and serum cytokine levels in mining populations in Amazonian Brazil: a cross-sectional study |
| Q40153822 | Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model |
| Q48502389 | Moving towards a molecular taxonomy of autoimmune rheumatic diseases |
| Q90415387 | Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece |
| Q35281962 | Myositis autoantibodies and clinical phenotypes. |
| Q90669513 | Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease |
| Q36917458 | Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses |
| Q35954658 | Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency |
| Q93140219 | Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation |
| Q36701466 | Pulmonary involvement in systemic sclerosis: A clinical profile |
| Q30458135 | Role of 2D strain in the early identification of left ventricular dysfunction and in the risk stratification of systemic sclerosis patients |
| Q33737250 | Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). |
| Q50329525 | Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study. |
| Q27021067 | Systemic sclerosis: commonly asked questions by rheumatologists |
| Q34779998 | The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases |
| Q43120878 | The changing landscape of the clinical value of the PM/Scl autoantibody system |
| Q36592069 | The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. |
| Q88801489 | The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease |
| Q24805079 | The use and abuse of commercial kits used to detect autoantibodies |
| Q37381549 | Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives |
| Q50230077 | Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. |
| Q38542317 | Update on systemic sclerosis |
| Q90395598 | VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways |
| Q79811339 | [Current pathophysiological aspects of systemic sclerosis] |
| Q79375343 | [Laboratory diagnostics of systemic autoimmune diseases. Part 1. Collagenoses] |
| Q64046177 | [Systemic sclerosis: pathophysiology of a multifaceted disease] |
Search more.